Post-effective amendment to a registration statement that is not immediately effective upon filing

STOCK-BASED COMPENSATION (Tables)

v3.25.2
STOCK-BASED COMPENSATION (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]    
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS

The Company has recorded stock-based compensation expense related to the issuance of restricted stock awards in the following line items in the accompanying condensed consolidated statements of operations:

 

    2025     2024  
    Three Months Ended
March 31,
 
    2025     2024  
             
Research and development   $ 21,250     $ 21,882  
General and administrative     305,366       260,731  
Total stock-based compensation expense   $ 326,616     $ 282,613  

The Company has recorded stock-based compensation expense related to the issuance of restricted stock awards in the following line items in the accompanying condensed consolidated statements of operations:

 

    2024     2023  
             
Research and development   $ 99,174     $ 37,131  
Selling, general and administrative     890,507       711,692  
Total stock-based compensation expense   $ 989,681     $ 748,823  
SUMMARY OF OPTION ACTIVITY

The following table summarizes stock option activity under the 2014 Plan and 2024 Plan:

 

    Number of
options
    Weighted-average
exercise price
    Weighted-average
remaining contractual
term (in years)
    Aggregate
intrinsic value
 
Outstanding at December 31, 2024     304,125     $ 6.95       4.45        
Granted                        
Exercised                        
Forfeited                        
Outstanding at March 31, 2025     304,125     $ 6.95       4.20        
                                 
Vested and exercisable at March 31, 2025     304,125     $ 6.95       4.20        

The following table summarizes stock option activity under the 2014 and 2024 Plans:

 

   

Number of

options

   

Weighted-

average

exercise price

   

Weighted-

average

remaining

contractual

term (in years)

   

Aggregate

intrinsic value

 
Outstanding at December 31, 2023     683,695     $ 3.99       2.9     $ 158,332  
Granted                        
Exercised     (208,031 )     1.16              
Forfeited     (171,539 )     2.16              
Outstanding at December 31, 2024     304,125     $ 6.95       4.20     $  
                                 
Vested and exercisable at December 31, 2024     304,125     $ 6.95       4.20     $  
SUMMARY OF RESTRICTED STOCK AWARD

The following table summarizes restricted stock award activity under the 2014 Plan and 2024 Plan:

 

      Number of                 As of March 31, 2025  
      restricted
stock awards
(RSA)
    Weighted-
average
grant price
    FMV on
grant date
    Vested
number
of RSA
    Unvested
number
of RSA
 
Balance at December 31, 2024       1,326,861     $ 1.99     $ 2,636,259       1,072,838       254,023  
Granted       253,398       0.84       212,875       66,658       186,740  
Forfeited       (10,289 )     0.81       (8,334 )           (10,289 )
Balance at March 31, 2025       1,569,970     $ 2.24     $ 2,840,800       1,139,496       430,474  

The following table summarizes restricted stock award activity under the 2014 and 2024 Plan:

 

                      As of December 31, 2024  
    Number of
restricted
stock awards
(RSA)
    Weighted-
average
grant price
    FMV on
grant date
    Vested
number
of RSA
    Unvested
number
of RSA
 
Balance at December 31, 2023     540,969     $ 2.24     $ 1,209,400       462,298       78,671  
Granted     865,423       1.81       1,570,834       517,941       347,482  
Forfeited     (77,096 )     1.80       (139,173 )           (77,096 )
Balance at December 31, 2024     1,329,296     $ 2.24     $ 2,641,061       980,239       349,057